Sana Biotechnology (SANA) Non-Current Assets (2020 - 2026)
Sana Biotechnology (SANA) posted Non-Current Assets of $261.9 million for Q1 2026, down 2.35% sequentially from $268.2 million in Q4 2025, and down 21.29% YoY from $332.7 million in Q1 2025.
Sana Biotechnology (SANA) Non-Current Assets (2020 - 2026) Analysis & Trends
Sana Biotechnology has reported Non-Current Assets for 7 years, with the latest figure at $261.9 million in Q1 2026.
- Quarterly Non-Current Assets fell 21.29% year-over-year to $261.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (down 21.38% YoY) and the FY2025 annual result came in at $268.2 million, down 21.16% from the prior year.
- Non-Current Assets slipped to $261.9 million in Q1 2026 per SANA's latest filing, from $268.2 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $524.4 million in Q1 2022 and troughed at $261.9 million in Q1 2026.
- A 5-year average of $355.7 million and a median of $351.9 million in 2023 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 55.61% in 2022, down 35.82% in 2022.
- Over 5 years, Non-Current Assets stood at $378.3 million in 2022, then decreased by 7.01% to $351.8 million in 2023, then decreased by 3.29% to $340.2 million in 2024, then fell by 21.16% to $268.2 million in 2025, then decreased by 2.35% to $261.9 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $261.9 million, $268.2 million, and $273.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Sana Biotechnology | 1.06 Bn | 1.06 Bn | - | 260.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 260.89 Mn |
| Mar 31, 2026 | 261.90 Mn |
| Dec 31, 2025 | 268.21 Mn |
| Sep 30, 2025 | 273.67 Mn |
| Jun 30, 2025 | 279.14 Mn |
| Mar 31, 2025 | 332.74 Mn |
| Dec 31, 2024 | 340.21 Mn |
| Sep 30, 2024 | 349.24 Mn |
| Jun 30, 2024 | 355.21 Mn |
| Mar 31, 2024 | 360.11 Mn |
| Dec 31, 2023 | 351.78 Mn |
| Sep 30, 2023 | 351.92 Mn |
| Jun 30, 2023 | 368.53 Mn |
| Mar 31, 2023 | 377.02 Mn |
| Dec 31, 2022 | 378.28 Mn |
| Sep 30, 2022 | 397.85 Mn |
| Jun 30, 2022 | 476.68 Mn |
| Mar 31, 2022 | 524.39 Mn |
| Dec 31, 2021 | 571.31 Mn |
| Sep 30, 2021 | 619.91 Mn |